These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

611 related items for PubMed ID: 16646673

  • 1. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
    Gazitt Y, Akay C, Thomas C.
    Stem Cells Dev; 2006 Apr; 15(2):269-77. PubMed ID: 16646673
    [Abstract] [Full Text] [Related]

  • 2. Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
    Lonial S, Akhtari M, Kaufman J, Torre C, Lechowicz MJ, Flowers C, Sinha R, Khoury HJ, Langston AA, Waller EK.
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):460-7. PubMed ID: 23201472
    [Abstract] [Full Text] [Related]

  • 3. Granulocyte colony-stimulating factor mobilizes more dendritic cell subsets than granulocyte-macrophage colony-stimulating factor with no polarization of dendritic cell subsets in normal donors.
    Shaughnessy PJ, Bachier C, Lemaistre CF, Akay C, Pollock BH, Gazitt Y.
    Stem Cells; 2006 Jul; 24(7):1789-97. PubMed ID: 16822885
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L, Fox RM, Szekely EM, Tainer N, Lazarus HM.
    J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
    [Abstract] [Full Text] [Related]

  • 7. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 8. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET, Towery JA, Miller AN, Kramer C, Hogan KR, Squires JE, Stuart RK, Costa LJ.
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D, Miller J, Verfaillie C, Burns L, Wagner J, Blazar B, Davies S, Miller W, Hannan P, Steinbuch M, Ramsay N, McGlave P.
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [Abstract] [Full Text] [Related]

  • 11. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A.
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [Abstract] [Full Text] [Related]

  • 12. Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's Lymphoma?
    Dazzi C, Cariello A, Rosti G, Argnani M, Sebastiani L, Ferrari E, Zornetta L, Monti G, Nicoletti P, Baioni M, Salvucci M, Scarpi E, Marangolo M.
    Leuk Lymphoma; 2000 Oct; 39(3-4):301-10. PubMed ID: 11342310
    [Abstract] [Full Text] [Related]

  • 13. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
    Shi YK, He XH, Han XH, Liu P, Yang JL, Zhou SY, Zhou AP, Zhang CG, Ai B.
    Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
    [Abstract] [Full Text] [Related]

  • 14. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
    Lonial S, Hicks M, Rosenthal H, Langston A, Redei I, Torre C, Duenzl M, Feinstein B, Cherry J, Waller EK.
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
    [Abstract] [Full Text] [Related]

  • 15. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
    Demirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, Chauncey T, Lilleby K, Storb R, Bensinger WI.
    Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
    [Abstract] [Full Text] [Related]

  • 16. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, Färber L, Burger KJ, Goldschmidt H, Hoelzer D, Haas R.
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [Abstract] [Full Text] [Related]

  • 17. Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34+ cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients.
    Gazitt Y, Liu Q.
    Stem Cells; 2001 Oct; 19(1):37-45. PubMed ID: 11209089
    [Abstract] [Full Text] [Related]

  • 18. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
    Sohn SK, Kim JG, Seo KW, Chae YS, Jung JT, Suh JS, Lee KB.
    Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
    [Abstract] [Full Text] [Related]

  • 19. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH, Schulman KA, Buckner CD.
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [Abstract] [Full Text] [Related]

  • 20. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
    Choi D, Perrin M, Hoffmann S, Chang AE, Ratanatharathorn V, Uberti J, McDonagh KT, Mulé JJ.
    Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.